# OnCo record iruplinalkib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/iruplinalkib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "iruplinalkib" ;
  schema:name "Iruplinalkib"@en ;
  schema:alternateName "Qixinke"@en ;
  schema:description "Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment."@en ;
  schema:url <https://onco.cc/drugs/iruplinalkib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=WX-0593> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Oral ALK and ROS1 tyrosine kinase inhibitor" ;
  onco:approval "CN 2023: ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/> ;
  onco:companies <https://onco.cc/companies/qilu-pharmaceutical/> ;
  onco:trials <https://onco.cc/trials/nct04632758/>, <https://onco.cc/trials/nct05765877/>, <https://onco.cc/trials/nct04641754/> .